EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pliant Therapeutics's enterprise value is €314.66 Mil.
Pliant Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.23 Mil. Therefore, Pliant Therapeutics's EV-to-Revenue for today is 1,374.04.
The historical rank and industry rank for Pliant Therapeutics's EV-to-Revenue or its related term are showing as below:
FRA:9PT'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.54 Med: 53.26 Max: 1980.77
Current: 1373.41
During the past 6 years, the highest EV-to-Revenue of Pliant Therapeutics was 1980.77. The lowest was -0.54. And the median was 53.26.
FRA:9PT's EV-to-Revenue is ranked worse than 96.82% of 1038
companies
in the Biotechnology industry
Industry Median: 8.22
vs FRA:9PT: 1373.41
The historical data trend for Pliant Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pliant Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Pliant Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pliant Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Pliant Therapeutics's EV-to-Revenue falls into.
Pliant Therapeutics's current Enterprise Value is €314.66 Mil.
Pliant Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pliant Therapeutics's share price for today is €12.30.
Pliant Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pliant Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Pliant Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Pliant Therapeutics (FRA:9PT) Business Description
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:9PT has been successfully added to your 